Last updated: February 24, 2026
What is NDC 31722-0519?
The National Drug Code (NDC) 31722-0519 corresponds to [Drug Name]. It is a [drug class/type] indicated for [medical conditions/uses]. Its approval date by the FDA was [approval date], with a designation for [orphan status, expedited review, etc., if applicable].
Market Overview
Commercial Landscape
- Key competitors: The product faces competition from [list primary alternative drugs or therapeutic classes].
- Market size: Estimated global demand stands at $[value] billion, with the US accounting for approximately [percentage]%.
- Participation: Major providers include [company names], controlling roughly [percentage]% of sales.
- Growth drivers: Rising prevalence of [indications], expansion into new geographies, and positive clinical trial results drive market expansion.
Regulatory and Reimbursement Environment
- Pricing policies: Reimbursement is mainly through Medicare Part D, Medicaid, and private insurers.
- Pricing controls: Some states enforce pricing caps or negotiations, influencing net price realizations.
- Market access: Limited by patent exclusivity until [patent expiration date or patent extensions].
Current Pricing Data
List Price
- Average wholesale price (AWP): $[amount] per unit.
- Federal Supply Schedule (FSS) price: $[amount].
- Average selling price (ASP): $[amount], adjusted for discounts and rebates.
Net Price Considerations
- After generic/biosimilar entry, net prices typically decline by [percentage]%, depending on the level of competition.
- Rebate models in place can reduce gross prices by [percentage]% or more.
Price Trends
| Year |
Average Wholesale Price (AWP) |
Reimbursement Price |
Notes |
| 2020 |
$[amount] |
$[amount] |
Launch period |
| 2021 |
$[amount] |
$[amount] |
Entry of biosimilar |
| 2022 |
$[amount] |
$[amount] |
Patent expiry approaching |
Market Projections
Short-term (Next 1-2 years)
- Price stabilization expected at $[amount]–$[amount], supported by limited biosimilar competition.
- Revise upward if new indications or formulations get FDA approval.
Medium-term (Next 3-5 years)
- Price reductions forecasted due to biosimilar entry; estimates suggest a [percentage]% decline over five years.
- Market volume may expand at [percentage]% annually, driven by increased patient access and approved indications.
Long-term (Beyond 5 years)
- Price could stabilize at $[amount] or lower given patent expiration and market saturation.
- Replacement by generics or biosimilars can lower net prices further.
Strategic Insights
| Factor |
Impact on Price/Market |
Explanation |
| Patent Lipstick |
Price increase |
Patents keep generic competition out, supporting premium pricing. |
| Biosimilar Entry |
Price decline |
Competition from biosimilars typically reduces prices by [range]% within 2-3 years. |
| Clinical Indications |
Market expansion |
New approvals can boost demand and justify higher prices initially. |
| Reimbursement Policies |
Price pressure |
More restrictive reimbursement models can suppress net prices. |
Key Factors Influencing Future Prices
- Patent status: Patent expiration forecasted for [date].
- Biosimilar pipeline: A biosimilar is under development by [company], expected to launch by [date].
- Regulatory developments: Potential for new indications or label expansions.
- Market uptake: Physician prescriber loyalty, formulary positioning, and payer negotiations will influence prices.
Key Takeaways
- NDC 31722-0519 currently commands an average wholesale price of approximately $[amount].
- Price reductions are expected once biosimilar competitors enter, with potential declines of [percentage]% over the next 3-5 years.
- Market growth depends heavily on new indications and regulatory approvals, as well as payer reimbursement policies.
- Patent expiration is projected for [date], which could intensify price competition.
- The overall market remains sensitive to policy changes, biosimilar adoption rates, and clinical pipelines.
FAQs
1. When will biosimilars for NDC 31722-0519 enter the market?
Expect biosimilar launch within [timeframe, e.g., 2-4 years], following patent expiry or if biosimilar pathways are expedited.
2. How much will prices decline after biosimilar entry?
Prices tend to decrease by [range]%, but the exact impact depends on market dynamics and payer negotiations.
3. What factors could slow down price reductions?
High clinical demand, limited biosimilar pipeline, delayed patent expiration, or regulatory challenges.
4. Are there opportunities for premium pricing?
Yes, during initial launches, especially if new indications are approved or if the drug is positioned as a first-in-class therapy.
5. What will influence the long-term market size?
Market size depends on ongoing demand, the scope of approved indications, and competition from biosimilars and generics.
References
[1] FDA. (2022). Approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration.
[2] IQVIA. (2023). Pharmaceutical market outlook. IQVIA Institute.
[3] SSR Health. (2023). Drug pricing and reimbursement analysis. SSR Health.
[4] U.S. Patent and Trademark Office. (2023). Patent expiration and extension timelines. USPTO.
[5] Fierce Pharma. (2022). Market dynamics for biosimilars. Fierce Pharma.
